Related Experiment Videos
Relationship between fibrinogen protein and fibrinogen function in postmyocardial infarction patients
E Réganon1, V Martínez-Sales, V Vila
1Research Center, La Fe University Hospital, Avda. Campanar, 21 46009 Valencia, Spain. reganon_ede@gva.es
Insights
Elevated fibrinogen function and clotting potential are linked to recurrent ischemic events in post-heart attack patients. Increased plasma fibrinogen and sialic acid suggest inflammation contributes to these cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Inflammation Research
Background:
- Chronic ischemic heart disease (IHD) poses significant risks for recurrent ischemic events.
- Understanding the role of coagulation factors and inflammation in IHD progression is crucial for risk stratification.
- Fibrinogen, a key clotting protein, and inflammatory markers are potential contributors to cardiovascular events.
Purpose of the Study:
- To investigate the association between plasma fibrinogen concentration and function, procoagulant markers, and inflammatory markers in patients with chronic IHD.
- To determine if these markers differentiate between IHD patients with and without recurrent ischemic events.
Main Methods:
- The study compared fibrinogen function index (FgFI), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin (TAT), fibrinogen protein (Fg-protein), high molecular weight fibrinogen (HMW-Fg), and plasma sialic acid (SA) levels.
- Participants included 11 post-MI patients with recurrent events, 19 post-MI patients without recurrent events, and 34 healthy controls.
Main Results:
- Post-MI patients with recurrent ischemic events showed significantly higher FgFI, F1+2, and TAT compared to controls.
- FgFI was significantly higher in patients with recurrent events versus those without.
- Both patient groups had higher Fg-protein and HMW-Fg than controls, with higher levels in the recurrent event group.
- Plasma SA levels were elevated in both patient groups compared to controls, correlating positively with fibrinogen levels.
Conclusions:
- Procoagulant factors, including fibrinogen, F1+2, and TAT, are actively involved in recurrent ischemic events in post-MI patients.
- Elevated plasma fibrinogen and SA suggest that inflammatory processes contribute to increased fibrinogen levels.
- The FgFI, indicating fibrinogen's clotting potential, is associated with ischemic events in chronic coronary artery disease.
Abstract:
The present study investigates the association between increases in the concentration and function of plasma fibrinogen in two groups of patients with chronic ischemic heart disease (11 with recurrent ischemic events and 19 free of these episodes) and in 34 healthy controls. The fibrinogen function index (fibrinogen function per unit of fibrinogen protein) (FgFI) was used as a measure of the fibrinogen clotting potential. The prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) were used as procoagulant markers. Plasma sialic acid (SA) was also evaluated as an inflammatory marker. No differences were found between FgFI (1.06+/-0.13 vs. 1.02+/-0.13), F1+2 (1.2+/-0.5 vs. 1.1+/-0.4 nmol/l) and TAT (2.5+/-1.3 vs. 2.5+/-0.7 microg/ml) in postinfarction patients without recurrent coronary ischemic events and the control group. However, postinfarction patients who suffered recurrent coronary ischemic events had significantly higher FgFI than patients without these symptoms (1.19+/-0.09 vs. 1.06+/-0.13), P<.01) and than the control group (1.19+/-0.09 vs. 1.02+/-0.13, P<.001). Moreover, the F1+2 (1.4+/-0.5 vs. 1.1+/-0.4 nmol/l, P<.05) and TAT (3.6+/-3.3 vs. 2.5+/-0.7 microg/ml, P<.05) were significantly higher in patients who suffered recurrent coronary ischemic events than in the control group. However, F1+2 and TAT were not different between patients with and without these symptoms. The fibrinogen protein (Fg-protein) concentration and high molecular weight fibrinogen (HMW-Fg) levels were significantly higher in both postinfarction patient groups than in the control group and in postinfarction patients with recurrent coronary ischemic events than in postinfarction patients without these symptoms. The plasma SA levels were significantly increased in postinfarction patients with and without recurrent coronary ischemia as compared with the control group. A positive correlation was found between fibrinogen and SA levels (r=.5, P<.01). In conclusion, our study indicates that the procoagulant factors, among which we include fibrinogen, F1+2 and TAT play a very active role in recurrent ischemic events in postmyocardial infarction patients. High plasma concentrations of both fibrinogen and SA suggests that fibrinogen becomes elevated as a consequence of inflammatory processes. The FgFI as an indicator of clotting potential of fibrinogen appears to be associated with ischemic events in chronic coronary artery disease.